for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Axonics Inc

AXNX.OQ

Latest Trade

68.38USD

Change

0.00(-0.00%)

Volume

92,983

Today's Range

66.55

 - 

68.66

52 Week Range

34.15

 - 

68.66

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
68.38
Open
66.55
Volume
92,983
3M AVG Volume
11.34
Today's High
68.66
Today's Low
66.55
52 Week High
68.66
52 Week Low
34.15
Shares Out (MIL)
45.33
Market Cap (MIL)
3,029.66
Forward P/E
-36.68
Dividend (Yield %)
--

Next Event

Q2 2021 Axonics Inc Earnings Release

Latest Developments

More

Axonics Receives FDA Approval Further Expanding MRI Labeling

Axonics® Announces Proposed Public Offering Of Common Stock

Axonics® Reports First Quarter 2021 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Axonics Inc

Axonics, Inc., formerly Axonics Modulation Technologies, Inc., is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. It has two clinical studies relating to its r-SNM System: a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. SNM therapy consists of two phases: an evaluation period, also called the external trial period, and a permanent implant for those patients who experience a successful external trial period. Its product offering also include Bulkamid, which is used to treat patients with stress urinary incontinence.

Industry

Medical Equipment & Supplies

Contact Info

26 Technology Dr

IRVINE, CA

92618-2380

United States

+1.949.3966322

https://www.axonics.com/

Executive Leadership

Michael H. Carrel

Independent Chairman of the Board

Danny L. Dearen

President, Chief Financial Officer

Raymond Wayne Cohen

Chief Executive Officer, Director

Rinda K. Sama

Chief Operating Officer

John Woock

Chief Marketing Officer

Key Stats

1.60 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.1K

2021(E)

0.2K
EPS (USD)

2018

-4.640

2019

-2.800

2020

-1.480

2021(E)

-1.815
Price To Earnings (TTM)
--
Price To Sales (TTM)
25.33
Price To Book (MRQ)
8.47
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
22.78
LT Debt To Equity (MRQ)
22.77
Return on Investment (TTM)
-20.31
Return on Equity (TTM)
-18.96

Latest News

Latest News

BRIEF-Axonics Receives FDA Approval for 3T Full-Body MRI Scans

* AXONICS® RECEIVES FDA APPROVAL FOR 3T FULL-BODY MRI SCANS Source text for Eikon: Further company coverage:

BRIEF-Axonics Reports FDA Approval Of Wireless Patient Remote Control With SmartMRI Technology

* AXONICS® ANNOUNCES U.S. FOOD & DRUG ADMINISTRATION APPROVAL OF WIRELESS PATIENT REMOTE CONTROL WITH SMARTMRI TECHNOLOGY

BRIEF-Andera Partners Cuts Share Stake In Axonics To 6.8% As Of May 15

* ANDERA PARTNERS CUTS SHARE STAKE IN AXONICS MODULATION TECHNOLOGIES TO 6.8% AS OF MAY 15 FROM A STAKE OF 8.7% AS OF JANUARY 22 - SEC FILING Source text: (https://bit.ly/36l74yZ) Further company coverage:

BRIEF-Axonics Says Public Offering Of 4 Mln Common Shares Priced At $32.50/Share

* AXONICS® ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Axonics Says Commenced Proposed Public Offering Of $100 Million In Shares

* AXONICS® ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Axonics Reports First Quarter 2020 Results

* Q1 EARNINGS PER SHARE VIEW $-0.60 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

BRIEF-Axonics Names Michael Carrel As Chairman Of Its Board Of Directors

* AXONICS NAMES MICHAEL H. CARREL AS CHAIRMAN OF ITS BOARD OF DIRECTORS

BRIEF-Axonics Modulation Says Most Employees To Take Temporary 20% Cut In Base Salary For Remainder Of Q2 2020

* AXONICS MODULATION TECHNOLOGIES INC - MOST EMPLOYEES WILL BE TAKING TEMPORARY 20% CUT IN BASE SALARY FOR REMAINDER OF Q2 2020 DUE TO COVID-19 IMPACT

BRIEF-Axonics® Says U.S. FDA Approves Implantable Neurostimulator

* AXONICS® ANNOUNCES U.S. FOOD & DRUG ADMINISTRATION APPROVAL OF NEXT GENERATION IMPLANTABLE NEUROSTIMULATOR

BRIEF-Axonics Submits PMA Supplement To U.S. FDA To Expand Full-Body MRI Labeling For 3T Scans

* AXONICS® SUBMITS PMA SUPPLEMENT TO U.S. FOOD & DRUG ADMINISTRATION TO EXPAND FULL-BODY MRI LABELING FOR 3T SCANS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-James Flynn Reports 5.23% Passive Stake In Axonics Modulation Technologies Inc As Of March 13

* JAMES FLYNN REPORTS 5.23% PASSIVE STAKE IN AXONICS MODULATION TECHNOLOGIES INC AS OF MARCH 13 - SEC FILING Source text for Eikon: Further company coverage:

BRIEF-Axonics Announces Filing Of Petitions Before The U.S. Patent And Trademark Office

* AXONICS® ANNOUNCES FILING OF PETITIONS BEFORE THE UNITED STATES PATENT AND TRADEMARK OFFICE CONTESTING THE VALIDITY OF MEDTRONIC PATENTS

BRIEF-Axonics Beats Qtrly Revenue Estimates

* AXONICS® ANNOUNCES FOURTH QUARTER AND FISCAL 2019 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up